N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Nagai, Takako ^a   Kanasaki, Megumi ^a   Srivastava, Swayam Prakash ^a   Nakamura, Yuka ^a   Ishigaki, Yasuhito ^a   Kitada, Munehiro ^a   Shi, Sen ^a   Kanasaki, Keizo ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETYL 4,5,6,7 TETRAHYDRO 2 PROPYL 3 [2' (1H TETRAZOL 5 YL) 4 BIPHENYLYLMETHYL]IMIDAZO[4,5 C]PYRIDINE 4 CARBOXYLIC ACID 1 ETHYLPROPOXYCARBONYLOXYMETHYL ESTER; ANTIFIBROTIC AGENT; CD31 ANTIGEN; CREATININE; FIBROBLAST GROWTH FACTOR RECEPTOR; IMIDAPRIL; INTERLEUKIN 1BETA; MICRORNA; N ACETYL SERYL ASPARTYL LYSYL PROLINE; SMAD3 PROTEIN; TANTALUM; TETRAPEPTIDE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; CYTOKINE; GROWTH INHIBITOR; MIRNLET7 MICRORNA, MOUSE; OLIGOPEPTIDE; SERASPENIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL TRANSFORMATION; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; METABOLISM; PATHOLOGY;

ANIMALS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; GROWTH INHIBITORS; MALE; MICE; MICRORNAS; OLIGOPEPTIDES; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84899528177     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/696475     Document Type: Article

References (33)

1. Kanasaki K.; Taduri G.; Koya D.; Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Frontiers in Endocrinology 2013 4, article 7 10.3389/fendo.2013.00007
2. He J.; Xu Y.; Koya D.; Kanasaki K.; Role of the endothelial-to- mesenchymal transition in renal fibrosis of chronic kidney disease. Clinical and Experimental Nephrology 2013 17 4 488 497 10.1007/s10157-013-0781-0
3. Kanasaki M.; Nagai T.; Kitada M.; Koya D.; Kanasaki K.; Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis and Tissue Repair 2011 4 1, article 25 2-s2.0-84855511123 10.1186/1755-1536-4-25
4. Kanasaki K.; Koya D.; Sugimoto T.; Isono M.; Kashiwagi A.; Haneda M.; N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF- β mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. Journal of the American Society of Nephrology 2003 14 4 863 872 2-s2.0-0037377993 10.1097/01.ASN.0000057544.95569.EC (Pubitemid 36359268)
5. Shibuya K.; Kanasaki K.; Isono M.; Sato H.; Omata M.; Sugimoto T.; Araki S.-I.; Isshiki K.; Kashiwagi A.; Haneda M.; Koya D.; N-acetyl-seryl-aspartyl- lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005 54 3 838 845 2-s2.0-20044389840 10.2337/diabetes.54.3.838 (Pubitemid 40322089)
6. Omata M.; Taniguchi H.; Koya D.; Kanasaki K.; Sho R.; Kato Y.; Kojima R.; Haneda M.; Inomata N.; N-acetyl-seryl-asparlyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. Journal of the American Society of Nephrology 2006 17 3 674 685 2-s2.0-33645452546 10.1681/ASN.2005040385
7. Liu J.-M.; Lawrence F.; Kovacevic M.; Bignon J.; Papadimitriou E.; Lallemand J.-Y.; Katsoris P.; Potier P.; Fromes Y.; Wdzieczak-Bakala J.; The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 2003 101 8 3014 3020 2-s2.0-0038281359 10.1182/blood-2002-07-2315 (Pubitemid 36857989)
8. Wang D.; Carretero O. A.; Yang X.-Y.; Rhaleb N.-E.; Liu Y.-H.; Liao T.-D.; Yang X.-P.; N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. American Journal of Physiology 2004 287 5 H2099 H2105 2-s2.0-7244237828 10.1152/ajpheart.00592.2004 (Pubitemid 39430749)
9. Fromes Y.; Liu J.-M.; Kovacevic M.; Bignon J.; Wdzieczak-Bakala J.; The tetrapeptide acetyl-serine-aspartyl-lysine-proline improves skin flap survival and accelerates wound healing. Wound Repair and Regeneration 2006 14 3 306 312 2-s2.0-33745532526 10.1111/j.1743-6109.2006.00125.x (Pubitemid 43979260)
10. Huff T.; Müller C. S. G.; Otto A. M.; Netzker R.; Hannappel E.; β -thymosins, small acidic peptides with multiple functions. The International Journal of Biochemistry and Cell Biology 2001 33 3 205 220 2-s2.0-0035052570 10.1016/S1357-2725(00)00087-X (Pubitemid 32304390)
11. Koutrafouri V.; Leondiadis L.; Avgoustakis K.; Livaniou E.; Czarnecki J.; Ithakissios D. S.; Evangelatos G. P.; Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochimica et Biophysica Acta 2001 1568 1 60 66 2-s2.0-0035824115 10.1016/S0304-4165(01)00200-8 (Pubitemid 33145385)
12. Philp D.; Huff T.; Gho Y. S.; Hannappel E.; Kleinman H. K.; The actin binding site on thymosin beta4 promotes angiogenesis. The FASEB Journal 2003 17 14 2103 2105 2-s2.0-0642303652
13. Malinda K. M.; Goldstein A. L.; Kleinman H. K.; Thymosin β 4 stimulates directional migration of human umbilical vein endothelial cells. The FASEB Journal 1997 11 6 474 481 2-s2.0-0030926245 (Pubitemid 27259989)
14. Smart N.; Risebro C. A.; Melville A. A. D.; Moses K.; Schwartz R. J.; Chien K. R.; Riley P. R.; Thymosin β 4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007 445 7124 177 182 2-s2.0-33846243239 10.1038/nature05383 (Pubitemid 46095717)
15. Sugimoto H.; Grahovac G.; Zeisberg M.; Kalluri R.; Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007 56 7 1825 1833 2-s2.0-34347375050 10.2337/db06-1226 (Pubitemid 47025452)
16. Hashimoto Y.; Ohashi R.; Kurosawa Y.; Minami K.; Kaji H.; Hayashida K.; Narita H.; Murata S.; Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. Journal of Cardiovascular Pharmacology 1998 31 4 568 575 2-s2.0-0031955613 10.1097/00005344-199804000-00015 (Pubitemid 28153134)
17. Brennan E. P.; Nolan K. A.; Borgeson E.; Gough O. S.; McEvoy C. M.; Docherty N. G.; Higgins D. F.; Murphy M.; Sadlier D. M.; Ali-Shah S. T.; Guiry P. J.; Savage D. A.; Maxwell A. P.; Martin F.; Godson C.; Consortium G.; Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1. Journal of the American Society of Nephrology 2013 24 627 637
18. Wang B.; Jha J. C.; Hagiwara S.; McClelland A. D.; Jandeleit-Dahm K.; Thomas M. C.; Cooper M. E.; Kantharidis P.; Transforming growth factor-beta1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney International 2014 85 352 361 10.1038/ki.2013.372
19. Chen P. Y.; Qin L.; Barnes C.; Charisse K.; Yi T.; Zhang X.; Ali R.; Medina P. P.; Yu J.; Slack F. J.; Anderson D. G.; Kotelianski V.; Wang F.; Tellides G.; Simons M.; FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Reports 2012 2 1684 1696
20. Cheng M. F.; Chen L. J.; Wang M. C.; Hsu C. T.; Cheng J. T.; Decrease of FGF receptor, (FGFR) and interstitial fibrosis in the kidney of streptozotocin-induced diabetic rats. Hormone and Metabolic Research 2014 46 1 1 7 10.1055/s-0033-1349090
21. Tzur G.; Israel A.; Levy A.; Benjamin H.; Meiri E.; Shufaro Y.; Meir K.; Khvalevsky E.; Spector Y.; Rojansky N.; Bentwich Z.; Reubinoff B. E.; Galun E.; Comprehensive gene and microRNA expression profiling reveals a role for microRNAs in human liver development. PLoS ONE 2009 4 10 2-s2.0-70449571951 10.1371/journal.pone.0007511 e7511
22. Zeisberg E. M.; Potenta S.; Xie L.; Zeisberg M.; Kalluri R.; Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research 2007 67 21 10123 10128 2-s2.0-35948945337 10.1158/0008-5472.CAN-07-3127 (Pubitemid 350070783)
23. Zeisberg E. M.; Potenta S. E.; Sugimoto H.; Zeisberg M.; Kalluri R.; Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. Journal of the American Society of Nephrology 2008 19 12 2282 2287 2-s2.0-55249103431 10.1681/ASN.2008050513
24. Zeisberg E. M.; Tarnavski O.; Zeisberg M.; Dorfman A. L.; McMullen J. R.; Gustafsson E.; Chandraker A.; Yuan X.; Pu W. T.; Roberts A. B.; Neilson E. G.; Sayegh M. H.; Izumo S.; Kalluri R.; Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nature Medicine 2007 13 8 952 961 2-s2.0-34547676391 10.1038/nm1613 (Pubitemid 47222040)
25. Li J.; Qu X.; Bertram J. F.; Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. The American Journal of Pathology 2009 175 4 1380 1388 2-s2.0-73549092294 10.2353/ajpath.2009.090096
26. Meng X. M.; Chung A. C.; Lan H. Y.; Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clinical Science 2013 124 243 254
27. LeBleu V. S.; Taduri G.; O'Connell J.; Teng Y.; Cooke V. G.; Woda C.; Sugimoto H.; Kalluri R.; Origin and function of myofibroblasts in kidney fibrosis. Nature Medicine 2013 19 1047 1053
28. Li P.; Xiao H. D.; Xu J.; Ong F. S.; Kwon M.; Roman J.; Gal A.; Bernstein K. E.; Fuchs S.; Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. The American Journal of Pathology 2010 177 3 1113 1121 2-s2.0-77956524295 10.2353/ajpath.2010.081127
29. Junot C.; Gonzales M.-F.; Ezan E.; Cotton J.; Vazeux G.; Michaud A.; Azizi M.; Vassiliou S.; Yiotakis A.; Corvol P.; Dive V.; RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. Journal of Pharmacology and Experimental Therapeutics 2001 297 2 606 611 2-s2.0-0035042245 (Pubitemid 32377991)
30. Vazeux G.; Cotton J.; Cuniasse P.; Dive V.; Potency and selectivity of RXP407 on human, rat, and mouse angiotensin-converting enzyme. Biochemical Pharmacology 2001 61 7 835 841 2-s2.0-0035313232 10.1016/S0006-2952(01)00550-0 (Pubitemid 32245566)
31. Kröger W. L.; Douglas R. G.; O'Neill H. G.; Dive V.; Sturrock E. D.; Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry 2009 48 35 8405 8412 2-s2.0-69749126456 10.1021/bi9011226
32. Anthony C. S.; Corradi H. R.; Schwager S. L. U.; Redelinghuys P.; Georgiadis D.; Dive V.; Acharya K. R.; Sturrock E. D.; The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407. The Journal of Biological Chemistry 2010 285 46 35685 35693 2-s2.0-78149236201 10.1074/jbc.M110.167866
33. Sugimoto H.; LeBleu V. S.; Bosukonda D.; Keck P.; Taduri G.; Bechtel W.; Okada H.; Carlson W. Jr.; Bey P.; Rusckowski M.; Tampe B.; Tampe D.; Kanasaki K.; Zeisberg M.; Kalluri R.; Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nature Medicine 2012 18 3 396 404 2-s2.0-84858008133 10.1038/nm.2629